<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02480998</url>
  </required_header>
  <id_info>
    <org_study_id>IY_IFEZ_Q120</org_study_id>
    <nct_id>NCT02480998</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults</brief_title>
  <official_title>A Randomized, Double-blind, Active Comparator, Phase I/Ⅱa Clinical Trial to Assess the Safety and Immunogenicity of the 'IL-YANG Flu Vaccine Quadrivalent Inj.' in Healthy Korean Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Il-Yang Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Il-Yang Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety, tolerability and immunogenicity of IL-YANG quadrivalent&#xD;
      vaccine versus IL-YANG trivalent vaccine after a single intramuscular administration in&#xD;
      healthy Korean males and females 19 to &lt; 65 years of age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, active-controlled, phase I/Ⅱa clinical trial.&#xD;
&#xD;
      During the Part A phase, all safety data collected from the 12 subjects enrolled in the Part&#xD;
      A phase will be analyzed to determine the safety and tolerability of the investigational&#xD;
      product, which should include any solicited and unsolicited adverse drug reactions occurring&#xD;
      for the first 7 days after vaccination and any adverse events occurring for 28 days after&#xD;
      vaccination. Antibody titer test will be also performed to evaluate the efficacy&#xD;
      (immunogenicity) of the investigational product. During the Part B phase, a total of 72&#xD;
      subjects will be enrolled, and all safety data (including all adverse events) and&#xD;
      immunogenicity data will be analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion Rate</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects achieving seroconversion* for HI antibody after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects achieving seroprotection* for HI antibody after vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMR</measure>
    <time_frame>28 days</time_frame>
    <description>Geometric Mean Ratio of post vaccination HI geometric mean titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT</measure>
    <time_frame>28 days</time_frame>
    <description>Geometric Mean Titer of post vaccination HI geometric mean titers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>IL-YANG Flu Vaccine QIV 0.5mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 0.5mL dose administrated as an intramuscular injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IL-YANG Flu Vaccine TIV 0.5mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 0.5mL dose administrated as an intramuscular injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-YANG Flu Vaccine QIV 0.5mL</intervention_name>
    <arm_group_label>IL-YANG Flu Vaccine QIV 0.5mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-YANG Flu Vaccine TIV 0.5mL</intervention_name>
    <arm_group_label>IL-YANG Flu Vaccine TIV 0.5mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women 19 to &lt; 65 years of age at screening&#xD;
&#xD;
          -  Body weight within ±20% of ideal body weight at screening&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum beta-hCG at visit 2; and&#xD;
             agree to use a proper contraceptive method for 1 month after vaccination (starting&#xD;
             from 3 months before screening), using a medication or device that does not have any&#xD;
             drug-interaction with the investigational product.&#xD;
&#xD;
          -  Subjects with no congenital or chronic disease who were considered suitable for the&#xD;
             study after screening assessments (investigator's opinion, medical history, physical&#xD;
             examination, laboratory test, chest X-ray, and ECG) conducted no later than 28 days&#xD;
             prior to vaccination&#xD;
&#xD;
          -  Subjects who were given, and fully understood, the information about the study, and&#xD;
             have provided voluntary written informed consent to participate in the study and to&#xD;
             comply with all applicable study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with known allergy to eggs, chicken, or any components of the investigational&#xD;
             product&#xD;
&#xD;
          -  Subjects who had received an influenza vaccine within the last 6 months prior to study&#xD;
             entry&#xD;
&#xD;
          -  Subjects who have known or suspected infection with HAV, HBV, HCV, HIV or VDRL&#xD;
&#xD;
          -  Subjects who have concurrent or a past history of, immune deficiency disease&#xD;
&#xD;
          -  Subject with a history of Guillain-Barre syndrome&#xD;
&#xD;
          -  Subject with hemophilia or thrombocytopenia or being treated with an anticoagulant,&#xD;
             who are at increased risk of serious bleeding during intramuscular injection&#xD;
&#xD;
          -  Subjects with known allergy to a drug, food or latex, who had a history of anaphylaxis&#xD;
&#xD;
          -  Subjects who had an acute fever with body temperature &gt; 38.0 Cº within 72 hours prior&#xD;
             to administration of the investigational product or symptoms of suspected acute&#xD;
             disease within 14 days prior to administration of the investigational product&#xD;
&#xD;
          -  Subjects who had received another vaccine within 28 days before administration of the&#xD;
             investigational product or are planning to receive another vaccine during the study.&#xD;
&#xD;
          -  Subjects who had participated in another clinical trial within the 30 days before&#xD;
             administration of the investigational product.&#xD;
&#xD;
          -  Subjects who had previously received blood-derived products (including immunoglobulin)&#xD;
             within the last 3 months prior to administration of the Investigational product, or&#xD;
             are scheduled to receive a treatment with blood-derived products during the study&#xD;
&#xD;
          -  Subjects who had received, or are scheduled to receive, systemic immunosuppressive&#xD;
             therapy, radiation therapy or high-dose steroid therapy within the last 6 months prior&#xD;
             to administration of the study&#xD;
&#xD;
          -  Subjects with a history of drug abuse within the last 6 months prior to vaccination,&#xD;
             or is suspected of drug abuse&#xD;
&#xD;
          -  Subjects with excessive consumption of caffeine, alcohol, or tobacco&#xD;
&#xD;
          -  Subjects with other clinically significant medical or psychiatric illness who in the&#xD;
             investigator's opinion, are not be suitable for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 11, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2015</study_first_posted>
  <results_first_submitted>August 30, 2018</results_first_submitted>
  <results_first_submitted_qc>August 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 28, 2018</results_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IL-YANG Flu Vaccine QIV 0.5mL</title>
          <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine QIV 0.5mL</description>
        </group>
        <group group_id="P2">
          <title>IL-YANG Flu Vaccine TIV 0.5mL</title>
          <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine TIV 0.5mL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IL-YANG Flu Vaccine QIV 0.5mL</title>
          <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine QIV 0.5mL</description>
        </group>
        <group group_id="B2">
          <title>IL-YANG Flu Vaccine TIV 0.5mL</title>
          <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine TIV 0.5mL</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.77" spread="7.01"/>
                    <measurement group_id="B2" value="27.75" spread="8.48"/>
                    <measurement group_id="B3" value="27.10" spread="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Rate</title>
        <description>Percentage of subjects achieving seroconversion* for HI antibody after vaccination</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Flu Vaccine QIV 0.5mL</title>
            <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine QIV 0.5mL</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Flu Vaccine TIV 0.5mL</title>
            <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine TIV 0.5mL</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate</title>
          <description>Percentage of subjects achieving seroconversion* for HI antibody after vaccination</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.93" lower_limit="46.04" upper_limit="71.81"/>
                    <measurement group_id="O2" value="64.29" lower_limit="46.54" upper_limit="82.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.29" lower_limit="51.74" upper_limit="76.84"/>
                    <measurement group_id="O2" value="53.57" lower_limit="35.10" upper_limit="72.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.36" lower_limit="42.34" upper_limit="68.38"/>
                    <measurement group_id="O2" value="35.71" lower_limit="17.97" upper_limit="53.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.43" lower_limit="33.37" upper_limit="59.49"/>
                    <measurement group_id="O2" value="14.29" lower_limit="1.32" upper_limit="27.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate</title>
        <description>Percentage of subjects achieving seroprotection* for HI antibody after vaccination</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Flu Vaccine QIV 0.5mL</title>
            <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine QIV 0.5mL</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Flu Vaccine TIV 0.5mL</title>
            <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine TIV 0.5mL</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate</title>
          <description>Percentage of subjects achieving seroprotection* for HI antibody after vaccination</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.64" lower_limit="88.75" upper_limit="100.00"/>
                    <measurement group_id="O2" value="85.71" lower_limit="72.75" upper_limit="98.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.43" lower_limit="91.57" upper_limit="100.00"/>
                    <measurement group_id="O2" value="82.14" lower_limit="67.96" upper_limit="96.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.50" lower_limit="78.84" upper_limit="96.16"/>
                    <measurement group_id="O2" value="78.57" lower_limit="63.37" upper_limit="93.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.57" lower_limit="67.82" upper_limit="89.32"/>
                    <measurement group_id="O2" value="64.29" lower_limit="46.54" upper_limit="82.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMR</title>
        <description>Geometric Mean Ratio of post vaccination HI geometric mean titers</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Flu Vaccine QIV 0.5mL</title>
            <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine QIV 0.5mL&#xD;
56</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Flu Vaccine TIV 0.5mL</title>
            <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine TIV 0.5mL&#xD;
28</description>
          </group>
        </group_list>
        <measure>
          <title>GMR</title>
          <description>Geometric Mean Ratio of post vaccination HI geometric mean titers</description>
          <units>Ratio of GMT titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.32" lower_limit="3.39" upper_limit="8.35"/>
                    <measurement group_id="O2" value="8.41" lower_limit="4.71" upper_limit="15.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.90" lower_limit="4.25" upper_limit="11.19"/>
                    <measurement group_id="O2" value="6.73" lower_limit="3.411" upper_limit="14.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Massachusetts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" lower_limit="2.82" upper_limit="5.27"/>
                    <measurement group_id="O2" value="2.90" lower_limit="1.67" upper_limit="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" lower_limit="2.52" upper_limit="4.06"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.40" upper_limit="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT</title>
        <description>Geometric Mean Titer of post vaccination HI geometric mean titers</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Flu Vaccine QIV 0.5mL</title>
            <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine QIV 0.5mL</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Flu Vaccine TIV 0.5mL</title>
            <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine TIV 0.5mL</description>
          </group>
        </group_list>
        <measure>
          <title>GMT</title>
          <description>Geometric Mean Titer of post vaccination HI geometric mean titers</description>
          <units>HI titer of post vaccination</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="97.31" upper_limit="168.50"/>
                    <measurement group_id="O2" value="110.40" lower_limit="69.30" upper_limit="175.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.70" lower_limit="132.10" upper_limit="234.20"/>
                    <measurement group_id="O2" value="128.00" lower_limit="69.42" upper_limit="236.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Massachusetts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.36" lower_limit="58.97" upper_limit="91.27"/>
                    <measurement group_id="O2" value="51.24" lower_limit="32.99" upper_limit="79.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.52" lower_limit="44.21" upper_limit="62.39"/>
                    <measurement group_id="O2" value="36.23" lower_limit="28.51" upper_limit="46.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IL-YANG Flu Vaccine QIV 0.5mL</title>
          <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine QIV 0.5mL</description>
        </group>
        <group group_id="E2">
          <title>IL-YANG Flu Vaccine TIV 0.5mL</title>
          <description>A single 0.5mL dose administrated as an intramuscular injection.&#xD;
IL-YANG Flu Vaccine TIV 0.5mL</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Dong-suck Lim, CI</name_or_title>
      <organization>The catholic university of Korea, Seoul ST. Marry's Hospital</organization>
      <phone>+82-2-2258-7327</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

